Tag Archives: subcutaneous dosing

Roche Reports Zero Treatment-Requiring Bleeds with NXT007 in Phase I/II Haemophilia A Study

(IN BRIEF) Roche presented positive phase I/II data for NXT007, its Chugai-engineered bispecific antibody for haemophilia A, at the 2025 ISTH Congress. In the NXTAGE study’s highest-dose cohorts (B-3 and B-4), none of the 30 participants experienced bleeds requiring treatment, … Read the full press release